SABCS: Novel Endocrine Therapy Reduces the Risk of Breast Cancer Recurrence
December 11, 2025
December 11, 2025
LOS ANGELES, California, Dec. 11 -- The UCLA Health issued the following news release:
* * *
SABCS: Novel endocrine therapy reduces the risk of breast cancer recurrence
Study is the first large scale clinical trial to show a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer
*
In an international study led by UCLA, researchers have shown that gire . . .
* * *
SABCS: Novel endocrine therapy reduces the risk of breast cancer recurrence
Study is the first large scale clinical trial to show a new oral endocrine therapy outperforms the long-standing standard therapies used for early-stage HR-positive/HER2-negative breast cancer
*
In an international study led by UCLA, researchers have shown that gire . . .